IMP3, CDK4, MDM2 and β-catenin expression in Enchondroma and Central Chondrosarcoma: Diagnostic and prognostic utility.

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Clinics Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI:10.1016/j.clinsp.2024.100483

Daniele Moraes Losada, Maurício Etchebehere, Francisco Fontes Cintra, Eliane Maria Ingrid Amstalden

{"title":"IMP3, CDK4, MDM2 and β-catenin expression in Enchondroma and Central Chondrosarcoma: Diagnostic and prognostic utility.","authors":"Daniele Moraes Losada, Maurício Etchebehere, Francisco Fontes Cintra, Eliane Maria Ingrid Amstalden","doi":"10.1016/j.clinsp.2024.100483","DOIUrl":null,"url":null,"abstract":"Introduction: The role of IMP3, CDK4, MDM2 and β-catenin proteins in Enchondroma and Central Chondrosarcoma is not totally understood. The aim of this study is to evaluate the immunoexpression of these proteins, associating histological grade, clinical data and prognosis to these tumors.Methods: This is a retrospective-analytical study of 32 Enchondroma and 70 Central Chondrosarcoma.Results: IMP3, CDK4, MDM2 and β-catenin expression was observed in 22.82 %, 13.82 %, 17.17 % and in 8.8 % of cases, respectively. All Enchondromas positive for these immunomarkers were located in short tubular bones. The positivity for these antibodies is directly proportional to Chondrosarcoma's histological grade increase. No difference was found between Enchondroma and Chondrosarcoma, Grade 1 for IMP3, CDK4 and ß-catenin positivity. Significant metastasis outcome was observed for IMP3, CDK4, MDM2 and death for MDM2 expression.Conclusion: IMP3, CDK4, MDM2 and β-catenin expression in Enchondromas of short bones phenotypically characterizes these tumors. Their expression has not proven to be useful either as diagnostic markers of these neoplasms or in distinguishing between Enchondroma and Chondrosarcoma, Grade 1. The significant immunoexpression of IMP3, CDK4 and MDM2 in metastatic Chondrosarcoma and the lower survival in those with positivity for MDM2 suggest a possible association of these proteins with tumor aggressiveness.","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"79 ","pages":"100483"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490761/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinsp.2024.100483","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The role of IMP3, CDK4, MDM2 and β-catenin proteins in Enchondroma and Central Chondrosarcoma is not totally understood. The aim of this study is to evaluate the immunoexpression of these proteins, associating histological grade, clinical data and prognosis to these tumors.

Methods: This is a retrospective-analytical study of 32 Enchondroma and 70 Central Chondrosarcoma.

Results: IMP3, CDK4, MDM2 and β-catenin expression was observed in 22.82 %, 13.82 %, 17.17 % and in 8.8 % of cases, respectively. All Enchondromas positive for these immunomarkers were located in short tubular bones. The positivity for these antibodies is directly proportional to Chondrosarcoma's histological grade increase. No difference was found between Enchondroma and Chondrosarcoma, Grade 1 for IMP3, CDK4 and ß-catenin positivity. Significant metastasis outcome was observed for IMP3, CDK4, MDM2 and death for MDM2 expression.

Conclusion: IMP3, CDK4, MDM2 and β-catenin expression in Enchondromas of short bones phenotypically characterizes these tumors. Their expression has not proven to be useful either as diagnostic markers of these neoplasms or in distinguishing between Enchondroma and Chondrosarcoma, Grade 1. The significant immunoexpression of IMP3, CDK4 and MDM2 in metastatic Chondrosarcoma and the lower survival in those with positivity for MDM2 suggest a possible association of these proteins with tumor aggressiveness.

查看原文本刊更多论文

软骨瘤和中央软骨肉瘤中IMP3、CDK4、MDM2和β-catenin的表达：诊断和预后作用。

简介IMP3、CDK4、MDM2和β-catenin蛋白在软骨瘤和中央软骨肉瘤中的作用尚不完全清楚。本研究旨在评估这些蛋白的免疫表达，并将组织学分级、临床数据和预后与这些肿瘤联系起来：这是一项对 32 例软骨瘤和 70 例中央软骨肉瘤的回顾性分析研究：结果：IMP3、CDK4、MDM2和β-catenin表达阳性的病例分别占22.82%、13.82%、17.17%和8.8%。所有对这些免疫标记物呈阳性的恩软骨瘤都位于短管状骨中。这些抗体的阳性率与软骨肉瘤组织学分级的增加成正比。在IMP3、CDK4和ß-catenin阳性方面，软骨瘤和软骨肉瘤1级之间没有发现差异。在IMP3、CDK4和MDM2表达方面观察到显著的转移结果，在MDM2表达方面观察到死亡结果：结论：短骨软骨瘤中IMP3、CDK4、MDM2和β-catenin的表达是这些肿瘤的表型特征。事实证明，它们的表达既不能作为这些肿瘤的诊断标志物，也不能用于区分1级软骨瘤和软骨肉瘤。在转移性软骨肉瘤中，IMP3、CDK4 和 MDM2 有明显的免疫表达，而 MDM2 阳性者的生存率较低，这表明这些蛋白可能与肿瘤的侵袭性有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinics 医学-医学：内科

CiteScore

4.10

自引率

3.70%

发文量

129

审稿时长

52 days

期刊介绍： CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.